Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022

Report Highlights

The global ovarian cancer therapeutic market reached $2.1 billion in 2017. The market should reach $2.9 billion by 2022, growing at a compound annual growth rate (CAGR) of 7.1% during 2017-2022.

Report Includes

• An overview of the global market for diagnostics and therapies for ovarian cancer, the fifth most common cancer in American women and the fourth most common cause of female cancer deaths.
• Country specific data and analysis for United States, Canada, Germany, United Kingdom, France, Italy, Spain, India, China, Japan, and Mexico.
• A breakdown of the markets by diagnostics and test, surgery, radiation therapy, and drug therapy.
• Discussion of ovarian cancer biology.
• Delineation of drugs approved to treat the disease, including chemotherapeutic and immunotherapeutic.
• Evaluation of the patent landscape.
• Comprehensive profiles of major players in the market, including Roche Holding AG, Novartis AG, Celgene Corp., and Pfizer, Inc.

Report Scope

This report will provide a detailed overview of ovarian cancer, highlighting treatment guidelines with information on the current and potential global market for ovarian cancer and treatments and testing technologies with detailed analysis of the competitive landscape, including new potential markets for novel products, diagnostics and therapeutics development.

The report covers the regulatory environment, current and new technologies, ovarian cancer incidence, market projections and market share along with the latest trends and new developments, recent approvals, the research and development pipeline, and blockbuster drugs. It also covers global and regional markets for ovarian cancer diagnostics and therapies, providing reasons for variations in the growth of the industry across regions.

The report also analyzes the competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie Inc, Astra Zeneca, Bristol-Myers Squibb Company, Celgene Corp., Clovis Oncology, Eli Lilly and Company, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Janssen Pharmaceuticals, Inc., Merck & Company, Inc., Myriad Genetics Inc., Novartis AG, Pfizer, Inc., Quest Diagnostics Inc., Roche Holding AG and Tesaro, Inc.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

• Organ-on-a-Chip: Global Markets (BIO188C)
• Building-Integrated Photovoltaics (BIPV): Technologies and Global Markets (EGY072F)
• Single-Cell Genomics and Proteomics: Emerging Technologies and Markets (BIO143C)
• E-commerce Regional Analysis Market: Middle East and North Africa (IFT311A)
• Antenna: Including Patch, Embedded, Fractal, Smart and Reflectors (IFT073G)